Literature DB >> 9675488

Saccharomyces boulardii fungemia in a patient receiving Ultra-levure therapy.

I Fredenucci1, M Chomarat, C Boucaud, J P Flandrois.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9675488     DOI： 10.1086/517685

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  7 in total

1.  Use of probiotics in gastrointestinal disorders: what to recommend?

Authors:  Elizabeth C Verna; Susan Lucak
Journal:  Therap Adv Gastroenterol       Date:  2010-09       Impact factor: 4.409

Review 2.  Risk and safety of probiotics.

Authors:  Shira Doron; David R Snydman
Journal:  Clin Infect Dis       Date:  2015-05-15       Impact factor: 9.079

Review 3.  Probiotics for antibiotic-associated diarrhea: do we have a verdict?

Authors:  Iyad Issa; Rami Moucari
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

Review 4.  Drug-induced diarrhoea.

Authors:  O Chassany; A Michaux; J F Bergmann
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

Review 5.  Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism.

Authors:  Marco Cassone; Pietro Serra; Francesca Mondello; Antonietta Girolamo; Sandro Scafetti; Eleonora Pistella; Mario Venditti
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

6.  Fatal Saccharomyces cerevisiae aortic graft infection.

Authors:  Davey Smith; David Metzgar; Christopher Wills; Joshua Fierer
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

7.  Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients.

Authors:  Beata Sulik-Tyszka; Emilian Snarski; Magda Niedźwiedzka; Małgorzata Augustyniak; Thorvald Nilsen Myhre; Anna Kacprzyk; Ewa Swoboda-Kopeć; Marta Roszkowska; Jadwiga Dwilewicz-Trojaczek; Wiesław Wiktor Jędrzejczak; Marta Wróblewska
Journal:  Probiotics Antimicrob Proteins       Date:  2018-06       Impact factor: 4.609
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.